52,279 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Hsbc Holdings PLC

Hsbc Holdings PLC purchased a new position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 52,279 shares of the company’s stock, valued at approximately $4,969,000.

Other large investors have also modified their holdings of the company. Rockefeller Capital Management L.P. raised its stake in BioNTech by 328.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock valued at $177,000 after acquiring an additional 1,423 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of BioNTech by 1,012.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after purchasing an additional 506 shares in the last quarter. Sankala Group LLC bought a new position in shares of BioNTech in the fourth quarter worth $248,000. Virtu Financial LLC increased its holdings in shares of BioNTech by 163.9% during the fourth quarter. Virtu Financial LLC now owns 11,244 shares of the company’s stock valued at $1,070,000 after purchasing an additional 6,984 shares during the period. Finally, Invesco Ltd. increased its holdings in shares of BioNTech by 9.0% during the fourth quarter. Invesco Ltd. now owns 80,841 shares of the company’s stock valued at $7,696,000 after purchasing an additional 6,685 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Wells Fargo & Company dropped their price target on shares of BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Berenberg Bank dropped their price objective on BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of BioNTech in a research report on Tuesday, March 17th. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $129.12.

BioNTech Trading Down 0.6%

NASDAQ BNTX opened at $92.98 on Friday. The firm’s 50 day moving average price is $92.07 and its two-hundred day moving average price is $97.97. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The stock has a market cap of $23.51 billion, a price-to-earnings ratio of -15.81 and a beta of 1.32.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The business had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%. Equities analysts anticipate that BioNTech SE Sponsored ADR will post -5.67 EPS for the current year.

BioNTech announced that its board has authorized a share buyback program on Thursday, May 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the completion of the sale, the chief operating officer owned 399,387 shares of the company’s stock, valued at $44,156,226.72. This trade represents a 11.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is owned by company insiders.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.